EP1310249A1 — Use of polyunsatured fatty acids for the primary prevention of major cardiovascular events
Assigned to PRO APARTS - INVESTIMENTOS E CONSULTORIA Lda · Expires 2003-05-14 · 23y expired
What this patent protects
The use of polyunsaturated fatty acids of the ω-3 series such as eicosapentaenoic acid (EPA, C 20:5 ω-3), docosahexaenoic acid (DHA, C 22:6 ω-3), or their pharmaceutically acceptable derivatives is described for the primary prevention of major cardiovascular events in subjects …
USPTO Abstract
The use of polyunsaturated fatty acids of the ω-3 series such as eicosapentaenoic acid (EPA, C 20:5 ω-3), docosahexaenoic acid (DHA, C 22:6 ω-3), or their pharmaceutically acceptable derivatives is described for the primary prevention of major cardiovascular events in subjects who have not undergone previous infarct episodes.
Drugs covered by this patent
- Epanova (OMEGA-3-CARBOXYLIC ACIDS) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.